The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Health Care Costs Associated With Muscle Weakness: A UK Population-Based Estimate
Open accessAbstract
Sarcopenia and muscle weakness are responsible for considerable health care expenditure but little is known about these costs in the UK. To address this, we estimated the excess economic burden for individuals with muscle weakness regarding the provision of health and social care among 442 men and women (aged 71-80 years) who participated in the Hertfordshire Cohort Study (UK). Muscle weakness, characterised by low grip strength, was defined according to the Foundation for the National Institutes of Health criteria (men < 26 kg, women < 16 kg). Costs associated with primary care consultations and visits, outpatient and inpatient secondary care, medications, and formal (paid) as well as informal care for each participant were calculated. Mean total costs per person and their corresponding components were compared between groups with and without muscle weakness. Prevalence of muscle weakness in the sample was 11%. Mean total annual costs for participants with muscle weakness were £4592 (CI £2962-£6221), with informal care, inpatient secondary care and primary care accounting for the majority of total costs (38%, 23% and 19%, respectively). For participants without muscle weakness, total annual costs were £1885 (CI £1542-£2228) and their three highest cost categories were informal care (26%), primary care (23%) and formal care (20%). Total excess costs associated with muscle weakness were £2707 per person per year, with informal care costs accounting for 46% of this difference. This results in an estimated annual excess cost in the UK of £2.5 billion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545
Lauretani, F., Russo, C. R., Bandinelli, S., Bartali, B., Cavazzini, C., Di Iorio, A., Corsi, A. M., Rantanen, T., Guralnik, J. M., & Ferrucci, L. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00246.2003 · Cited by 1,946
The healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., et al. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0517-y · Cited by 112
Self-citation
Cited by
Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers
Kirk, B., Zanker, J., & Duque, G. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12567 · Cited by 529
Sayer, A. A., Cooper, R., Arai, H., Cawthon, P. M., Ntsama Essomba, M.-J., Fielding, R. A., Grounds, M. D., Witham, M. D., & Cruz-Jentoft, A. J. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00550-w · Cited by 380
Understanding the gut microbiota and sarcopenia: a systematic review
Liu, C., Cheung, W., Li, J., Chow, S. K., Yu, J., Wong, S. H., Ip, M., Sung, J. J. Y., & Wong, R. M. Y. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12784 · Cited by 363
“7 in the USA and £2707 in the UK for a single sarcopenic patient hospitalized.(9,10) It is also estimated that”
BackgroundResistance exercise as a treatment for sarcopenia: prescription and delivery
Hurst, C., Robinson, S. M., Witham, M. D., Dodds, R. M., Granic, A., Buckland, C., De Biase, S., Finnegan, S., Rochester, L., Skelton, D. A., et al. (2022) · Age and Ageing · doi:10.1093/ageing/afac003 · Cited by 319
Self-citationCurrent and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Metadata
- Authors
- Pinedo-Villanueva, R., Westbury, L. D., Syddall, H. E., Sanchez-Santos, M. T., Dennison, E. M., Robinson, S. M., & Cooper, C.
- Venue
- Calcified Tissue International
- Published
- 2018-09-22
- Volume
- 104
- Issue
- 2
- Pages
- 137-144
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2894049215
- Cited by
- 221
- References
- 6
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.